Possible New Treatment for Spinal Cord Injuries Identified in Research Led by PVM Professor

Dr. Riyi Shi pictured

Research led by a Purdue Veterinary Medicine scholar shows that an experimental drug has promise as a potential therapy for spinal cord injuries in animal studies.  The compound, 4-aminopyridine-3-methanol, works in a similar way as a drug previously developed at Purdue, 4-aminopyridine (4-AP), which has been approved by the U.S. Food and Drug Administration to treat multiple sclerosis.

Dr. Riyi Shi, who holds a joint appointment as professor in Purdue Veterinary Medicine’s Department of Basic Medical Sciences, and in the Weldon School of Biomedical Engineering, was involved in the development of both drugs, and compared the two compounds in both cell cultures and animal models.  “For the first time, 4-aminopyridine-3-methanol is shown to restore function in chronic spinal cord injuries,” Dr. Shi says. “It also reduces neuropathic pain to a greater degree than 4-AP.

Dr. Shi further explains, “Because persistent chronic pain is a serious problem among patients with spinal cord injuries, 4-aminopyridine-3-methanol could potentially be used to reduce pain, independent of any motor benefits.”  He says an advantage of this drug is its broad therapeutic dosing range. “The minimum effective dose can be as low as 10 times less than 4-AP, but it can also be applied at a level that is five times as high.”

In spinal injuries even if the nerve fibers of the spinal cord itself, the axons, are intact, function can still be lost if there is damage to the fatty coating on the outside of nerve fibers, which is called the myelin sheath. When the myelin sheath is damaged, potassium channels underneath the coating open, disrupting the electrical signal. Both drugs work by closing these channels to restore the conduction of the axons.

“We are very encouraged by this preclinical study because about 10 years ago 4-AP, which is marketed as fampridine, dalfampridine, or Ampyra, was approved for MS, and both spinal cord injuries and MS share a similar mechanism of nerve signal conduction loss; they both could be caused by myelin damage,” Dr. Shi says. “The drug was approved for MS but not approved for spinal cord injuries because of concerns about potential toxicity and a narrow therapeutic dose range. So there is a big need for a better channel blocker.”

Dr. Shi and his team found that 4-aminopyridine-3-methanol is safer, more effective at closing the potassium channels — at least 50 percent more effective — and also much longer lasting.  The research is published in the May Journal of Neurotrauma, and was funded by the National Institutes of Health; the state of Indiana; the Science and Technology Commission of Shanghai Municipality, Shanghai, China; and grants from the Shanghai Bureau of Health, Shanghai, China.

Dr. Shi also is the co-founder of Neuro Vigor, a startup company with business interests of developing effective therapies for central nervous system neurodegenerative diseases and trauma.

Click here to view a complete news release about the research.

Writer(s): Steve Tally, steve@purdue.edu | pvmnews@purdue.edu

Recent Stories

“Paws Up” – brought to you by the PVM Wellness Committee

Today we’re sending a big “High Five” to Emma Wood, who is a Medical Oncology Client Liaison and the Client Liaison Team Lead for the Purdue Small Animal Reception Team, for the supportive energy she brings to her work every day.

In Memory: Former Veterinary Medical Library Staff Member Tonya Mull 

The Purdue Veterinary Medicine community is saddened to learn that Tonya R. Mull of Lafayette, Indiana, who served as a longtime Purdue Libraries staff member, including multiple years as a staff member in the Veterinary Medical Library, passed away October 18 at Franciscan Health Lafayette East.  She was 59.

PVM Symposium Offers MOAAR Education on Medicine of Aquatics, Amphibians and Reptiles

Veterinary professionals and students gathered recently at the Purdue University College of Veterinary Medicine to take advantage of a special opportunity to enhance their knowledge and expertise about the care and treatment of aquatic, amphibian, and reptilian species. The fifth biennial Medicine of Aquatics, Amphibians, and Reptiles (MOAAR) Symposium was held October 18–19, at Lynn Hall on Purdue University’s West Lafayette campus, bringing together veterinarians, veterinary technicians, students, and experts dedicated to the care of exotic species.

Local Veterinary Celebration Highlights Global Veterinary Education

Going global is a popular ambition in the Purdue University College of Veterinary Medicine as evidenced by the turnout for the college’s annual Global Engagement Fair last Friday, October 17. Held in the Veterinary Medical Library in Lynn Hall, the festive event featured international cuisine and displays about various study abroad opportunities available to Purdue DVM and Veterinary Technology students.